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We report anunusual case of atypical proximal tibial stress fracture (APTF) associatedwith intermittent use
of bisphosphonates (BPs) and persistently low serum alkaline phosphatase (ALP) levels. We describe the
case of a 63-year-old white woman who had experienced an APTF after 4 years of intermittent exposure to
alendronate given for recurrent metatarsal stress fractures. BP administration was stopped after the di-
agnosis of the APTF. A review of her previous serum ALP levels revealed they had been consistently low.
Adult hypophosphatasia (HPP) was diagnosed by the low serum ALP activity and elevated urine phos-
phoethanolamine levels. She was treated conservatively with analgesics. Adult HPP is an underrecognized
condition associatedwith atypical insufficiency fractures, andBPuse compounds this risk. To the best of our
knowledge, we report the first case of intermittent BP exposure preceding an APTF in an adult patient with
HPP, highlighting theuncommon site of the proximal tibia forBP-associated atypical insufficiency fractures,
the need to screen for HPP in those with persistently low ALP levels before they begin BP therapy, and the
importance of avoiding BP use in those with HPP.
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Hypophosphatasia (HPP) is a rare inherited disorder characterized by low serumALPactivity and
defective bone mineralization [1]. Atypical femoral fractures (AFFs) have been reported in adult
patients withHPP, bothwith andwithout longstanding use of bisphosphonates (BPs) [2, 3]. To the
best of our knowledge, we report the first case of a patient with HPP presenting with an atypical
proximal tibial stress fracture (APTF), associated with intermittent/occasional use of BPs.
1. Case Report
A 63-year-old white woman had presented in December 2018 with a 2-week history of
atraumatic pain in the right upper tibial region. She had no systemic symptoms. Her medical
Abbreviations: AFF, atypical femoral fracture; ALP, alkaline phosphatase; APTF, atypical proximal tibial stress fracture; ASBMR,
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history revealed repeated left and right metatarsal stress fractures that had occurred from
2009 to 2013. Her relevant medication history showed usage of alendronate (70 mg weekly)
that had begun in June 2014. However, she admitted to taking alendronate intermittently,
often missing the medication for #11 months at a time (Table 1). She had no history of oral
glucocorticoid use, and she had no dental issues. Her other medical history was pertinent for
laparoscopic resection of a right adrenal aldosterone-producing adenoma in 2011. Post-
operatively, her antihypertensive medications were stopped. On examination, she was in
good general condition with a body mass index of 36.1 kg/m2. Tenderness was present on
palpation along the upper shaft of the right tibia. A conventional radiograph showed peri-
osteal reaction with no evidence of cortical beaking or transverse (stress) fractures (Fig. 1). A
technetium-99m bone scan showed increased uptake in the region of the right proximal tibial
shaft (Fig. 2). The findings from a bone biopsy were consistent with a healing fracture with no
evidence of malignancy or infection. Her T-scores for bone mineral density on dual-energy
x-ray absorptiometry were 21.19 at the lumbar spine and 21.87 at the neck of femur. The
serum carboxy-terminal collagen crosslinks and N-terminal propeptide of type I pro-
collagen levels were normal at 430 ng/L (normal range, ,800 ng/L) and 49 mg/L (normal
range, 15 to 90 mg/L), respectively. Serum and urine protein electrophoresis did not detect a
monoclonal immunoglobulin.
At the time of the fracture, her serum biochemical parameters of bone metabolism were
normal: calcium, 2.38mmol/L; phosphate, 1.32mmol/L; ALP, 39U/L (normal range, 30 to 115U/
L); parathyroid hormone, 5.6 pmol/L (normal range, 1.6 to 6.9 pmol/L); 25-hydroxy vitamin D,
59 nmol/L (normal range, 50 to 150 nmol/L); and estimated glomerular filtration rate, 83 mL/
min. However, on reviewing her bone metabolic profile from 2009, all the parameters were
unremarkable, except for her serum ALP levels, which were frequently low, ranging from 23 to
28 U/L (normal range, 30 to 115 U/L). The higher ALP level at her presentation was likely in
response to her proximal tibial insufficiency fracture. The urine phosphoethanolamine level was
elevated at 13mmol/mol creatinine (normal range,,5), consistent with a diagnosis of HPP. Her
serum pyridoxal 50-phosphate (vitamin B6) was, however, within the normal range at 110 nmol/
L (normal range, 20 to 190 nmol/L). She was advised to stop taking the alendronate and was
treated conservatively with simple analgesics, calcium carbonate, vitamin D, and nonweight-
bearing with progressive, successful healing of the fracture. With resolution, her ALP and
carboxy-terminal collagen crosslinks levels had gradual decreased (31 U/L and 370 ng/L, re-
spectively). A repeat serum pyridoxal 50-phosphate test when she was not taking vitamin B6
supplements showed that the level had returned to the upper limit of normal (190 nmol/L).
2. Discussion
To the best of our knowledge, we report the first case of APTF in a patient with adult HPPwho
had been using only intermittent BP. Our report is unique regarding the location of the
fracture and that, unlike previously reported cases of AFFs in patients with HPP and long-
term regular exposure to BP [2], our patient was taking the BP only occasionally. In our
patient, the serum ALP levels had been previously low, although not recognized by the
Table 1. Prescription Record Indicating Occasional Use of Alendronate From 2014 to Fracture in
December 2018
Date of
Prescription
Expected Date of Repeat
Prescription
Actual Date of Repeat
Prescription
Estimated Period Without
Treatment, mo
23/6/2014 23/12/2014 11/6/2015 6
11/6/2015 11/12/2015 19/11/2016 11
19/11/2016 19/5/2017 14/2/2018 9
14/2/2018 14/8/2018 10/12/2018 4
The patient had been without treatment for #30 mo.
doi: 10.1210/js.2019-00265 | Journal of the Endocrine Society | 2083
treating physicians. The primary clinical utility of ALP is that elevated levels are used to
diagnose bone diseases associated with high bone turnover, such as osteomalacia and Paget
disease. Little attention has been given to low ALP values [1, 4]. The clinical features of adult
HPP include a propensity to fracture, the early loss of deciduous teeth, and the presence of
musculoskeletal pain [1]. A spectrum of disease severity in HPP exists that is inversely
related to the age of symptom onset (categorized into five forms according to symptom onset),
ranging from in utero fetal death with perinatal HPP to adult HPP. Odontohypophosphatasia
is themildest variant (isolated early shedding of deciduous teeth) [5]. The disease is caused by
loss-of-function mutations in the tissue nonspecific ALP gene. More than 300 mutations have
been identified, with both autosomal dominant and autosomal recessive inheritance patterns
[5]. The low ALP activity results in extracellular accumulation of inorganic pyrophosphate, a
potent inhibitor of hydroxyapatite formation and, thus, bone mineralization. BPs are struc-
turally similar to inorganic pyrophosphate, with earlier nonamino agents (e.g., etidronate)
Figure 1. Radiographs showing evolution of APTF in HPP. (A) Radiograph at her initial
presentation with pain showing only periosteal reaction along the proximal tibial shaft. (B)
Radiograph 1 mo later showing a nondisplaced pathological fracture through the proximal
tibial shaft and extending inferiorly through the metaphysis (arrows) with periosteal reaction
in the lateral tibial cortex. (C) Radiograph 2 mo after presentation showing a more
conspicuous fracture line, with evidence of early callus formation. (D) Radiograph 6 mo after
fracture showing bony union with mature callus.
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shown to inhibit bone mineralization through a similar mechanism with toxicity presenting
similar to that of HPP [2, 6, 7]. Newer agents are thought to inhibit bone remodeling through
alternative mechanisms [6].
AFFs were first recognized as a rare complication of BP treatment in 2005, and the
American Society of Bone and Mineral Research (ASBMR) released a position statement on
AFF in 2010 that was revised in 2014 [8]. The pathogenesis has not been fully elucidated.
However, these fractures share features with stress and insufficiency fractures in which
accumulated, unrepairedmicrotrauma leads to fracture, suggesting AFFsmight be related to
an inability to remodel and heal the damage after prolonged usage of BPs [9]. The ASBMR
taskforce on AFF reported a case definition that clearly delineates AFF from other minimal-
trauma subtrochanteric fractures; it does not make reference to nonfemoral fractures [8].
Nevertheless, fractures with similar morphology at other sites, including the proximal tibia,
have infrequently been reported with BP use and have been postulated to have the same
pathophysiology [9–11]. Patients with severe HPP are known to sustain AFFs [12]. Fur-
thermore, case reports have described AFFs in patients with HPP taking BPs (Table 2) [2,
13–15]. A further mechanism of insufficiency fractures in patients with HPP taking BPs has
Figure 2. Technetium-99m bone scan showing (A) prompt perfusion and (B) hyperemia in
the region of the right proximal tibial shaft.
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only recently been proposed. BPs, which are analogs of calcium pyrophosphate, could inhibit
the already reduced activity of ALP by binding to Zn21 and Mg21; both are needed for ALP
activity [2]. The combination of defective bone mineralization and pharmacologically im-
paired remodeling in these patients likely precipitates these fractures. Therefore, BPs would
be especially contraindicated for patients with HPP, demonstrating the importance of
screening for HPP before prescribing BPs to minimize the risk of insufficiency fractures.
Adult HPP can be easily overlooked, because patients typically present with recurrent,
poorly healing metatarsal stress fractures [1]. Adult HPP should be suspected especially in
patients with a diagnosis of osteoporosis and low serumALP levels before they started taking
BPs, after the exclusion of other causes of hypophosphatasemia [5]. Additional biochemical
evidence to support a diagnosis of HPP includes elevated levels of ALP substrates (i.e.,
plasma pyridoxal 50-phosphate, plasma or urine phosphoethanolamine, and plasma or
urinary inorganic pyrophosphate) [2]. The single finding of a low serum ALP level alone is
insufficient to diagnose HPP and, thus, requires confirmation by measuring the substrates of
this enzyme and, where available, mutational analysis of the tissue nonspecific ALP gene [5].
In our patient, the serial serum ALP levels were consistently low, along with an elevated
urinary level of phosphoethanolamine and high to normal pyridoxal 50-phosphate. Our
finding is in keeping with the report byMcKiernan et al. [16], which showed 61% of those with
HPP with low serum ALP levels having elevation of only one ALP substrate, either phos-
phoethanolamine or pyridoxal 50-phosphate, at diagnosis. A urinary inorganic pyrophosphate
level would be helpful additional information. Although essential to confirm the diagnosis,
genetic studies were not conducted for our patient. Neither of these tests are readily available
in Australia. The findings from the biochemical studies and the history of recurrent
metatarsal stress fractures in our patient were suggestive of a diagnosis of adult HPP [1].
The incidence of mild vs moderate forms of HPP in the adult population is thought to be
high, with an estimated prevalence of carriers of mild to moderate mutations of 1 in 6370 in
the European population [7]. The prevalence of asymptomatic HPP carriers could even be as
great as 1 in 250 to 300 persons [7]. These data indicate the need to consider an assessment for
HPP for patients presenting with minimal trauma or stress fractures, especially when
evaluating antiosteoporotic treatment with BP. Similar to our study, Sutton et al. [2] reported
the case of a patient with HPP initially misdiagnosed with osteoporosis, who had developed a
bilateral AFF after 4 years of treatment with BPs. Osteoporosis had also been initially
misdiagnosed in our patient after recurrent bilateral metatarsal fractures and treatment
with oral BPs. She had developed the fracture after 4 years of intermittent BP treatment. The
ASMBR definition for atypical insufficiency fractures is limited to the subtrochanteric femur
and diaphysis [8]. Except for the location in the proximal tibia, some of the ASBMR criteria
were evident in our patient, including a noncommunuted tibial fracture after no trauma,
prodromal pain for several weeks leading up to the fracture, and delayed fracture healing.
Table 2. Previous Reported Cases of Atypical Fractures in Patients With Hypophosphatasia
Taking Bisphosphonates
Investigator Fracture Site Bisphosphonate
Interval From BP Start
to Fracture, y
Genetic
Confirmation
Sutton et al.
[2]
AFF Alendronate (2.5 y), zoledronic
acid (1.5 y; 2 doses)
4 Yes
Righetti et al.
[13]
Bilateral AFF Alendronate 10 Yes
Doshi et al.
[14]
Bilateral
incomplete
AFF
Risedronate 2.5a No
Peris et al.
[15]
AFF Alendronate 8 Yes
aAn incomplete fracture was present before the patient had begun BP therapy, with progression occurring with
medication use.
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Involvement of a nonfemoral site highlights the risk in other weight-bearing bones and calls
for broadening the definition of “atypical fractures” [8, 9].
In conclusion, HPP is a relatively common, infrequently recognized, entity that is often
misdiagnosed as osteoporosis. The diagnosis of HPP should be suspected in those with a low
serum ALP level before BP treatment and should be excluded as a cause of minimal trauma
fractures. BP treatment should be avoided, owing to the increased risk of atypical fractures
(not only AFFs). The findings from the present case have highlighted these salient practice
points. Further studies are needed to elucidate the pathophysiology of atypical fractures.
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